Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
Open Access
- 1 November 2013
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (11), e146-e148
- https://doi.org/10.3324/haematol.2013.095372
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemiaHaematologica, 2012
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic LeukemiaCancer Cell, 2012
- Silent hypersensitivity toEscherichia coliasparaginase in children with acute lymphoblastic leukemiaLeukemia & Lymphoma, 2010
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathwaysProceedings of the National Academy of Sciences of the United States of America, 1996
- Failure of B-cell differentiation in mice lacking the transcription factor EBFNature, 1995
- Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocationCell, 1994